The dawn of the molecular era of the myelodysplastic syndromes

New England Journal of Medicine

Volumn 364, Issue 26, 2011, Pages 2545-2546

  Odenike, Olatoyosi ^a   Le Beau, Michelle M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CYTOPENIA; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG TARGETING; EDITORIAL; GENETIC DISORDER; GENETIC SCREENING; HIGH RISK PATIENT; HUMAN; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; THROMBOCYTOPENIA;

EID: 79959801405     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1102921     Document Type: Editorial

References (10)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
2. Olney HJ, Le Beau MM. The cytogenetics and molecular biology of the myelodysplastic syndromes. In: Steensma DP, ed. Myelodysplastic syndromes: pathobiology and clinical management. 2nd ed. New York: Informa Healthcare, 2008:49-86.
3. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011;29:504-15.
4. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. (Pubitemid 27132124)
5. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10. (Pubitemid 47315575)
6. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011;29:516-23.
7. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-61.
8. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-506.
9. Schanz J, Tuechler H, Sole F, et al. Cytogenetic risk features in MDS - update and present state. Blood 2009;114:2772. abstract.
10. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058-66.